JILIN AODONG(SZ:000623) Xin Lang Cai Jing·2025-09-29 05:58Group 1 - Jilin Aodong Pharmaceutical Group Co., Ltd. experienced a stock price increase of 5.23%, reaching 20.12 CNY per share, with a trading volume of 419 million CNY and a turnover rate of 1.80%, resulting in a total market capitalization of 24.061 billion CNY [1] - The company, established on March 20, 1993, and listed on October 28, 1996, specializes in the research, development, manufacturing, and sales of traditional Chinese medicine and biochemical drugs, while also expanding into health foods, food, breeding, and planting sectors [1] - The revenue composition of Jilin Aodong includes traditional Chinese medicine at 60.90%, wholesale and retail of chain pharmacies at 16.59%, chemical drugs at 12.73%, food at 7.39%, and other products at 1.76% [1] Group 2 - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Jilin Aodong, having increased its holdings by 1.9148 million shares in the second quarter, totaling 14.2479 million shares, which represents 1.2% of the circulating shares [2] - The Southern CSI 500 ETF (510500) has a current scale of 113.438 billion CNY, with a year-to-date return of 28.25%, ranking 1796 out of 4221 in its category, and a one-year return of 48.6%, ranking 1589 out of 3836 [2] Group 3 - The Southern CSI 500 Enhanced Strategy ETF (560100) holds 29,800 shares of Jilin Aodong, accounting for 0.63% of the fund's net value, making it the ninth-largest holding [4] - The Southern CSI 500 Enhanced Strategy ETF (560100) has a current scale of 80.4132 million CNY, with a year-to-date return of 27.63%, ranking 1852 out of 4221 in its category, and a one-year return of 45.75%, ranking 1710 out of 3836 [4]